IDEXX Laboratories (IDXX) has significantly rallied over the year with a 71% increase, driven by a bullish market sentiment, 'Dognostics' leadership, and continuous addition to portfolios like Congress Asset Management. Further boosts come from consistent earnings growth, with full-year financial results for 2025 set to release. The company's diagnostic growth and impressive share price momentum are driving a more durable investment narrative. Meanwhile, IDEXX has consistently outperformed its medical peers this year and appears undervalued according to some analysts.
IDXX has surged by nearly 15% in one day and shown outstanding execution amid economic challenges. A top growth stock for the long-term, IDEXX boasts a 65% return over the last year for its investors and is predicted to maintain strong growth. With an exceptional Q3 beat and guidance hike, the compelling investment case for the company seems set to change.
IDEXX beats Q2 and Q3 earnings estimates, underlining its strong revenue and EPS growth, leading to a price target increase to $700 by Piper Sandler, and has a strong long-term growth outlook according to Stifel.
Idexx Laboratories IDXX News Analytics from Thu, 10 Jul 2025 07:00:00 GMT to Sat, 10 Jan 2026 11:12:30 GMT -
Rating 8
- Innovation 7
- Information 8
- Rumor -7
